-
This 150-day, randomized, double-blind, placebo controlled trial (RCT) with 465 healthy adult volunteers (mean age 37 years old) was designed to examine the effects of probiotics on the incidence of upper respiratory tract infections (URTI).
-
The FDA has approved two drugs for the treatment of idiopathic pulmonary fibrosis (IPF). Pirfenidone is an antifibrotic agent and nintedanib is a tyrosine kinase inhibitor. Both products were approved on a fast-track priority review, with orphan status and breakthrough designation. Pirfenidone is marketed by InterMune as Esbriet and nintedanib as Ofev by Boehringer Ingelheim.
-
Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients with Isolated Systolic Hypertension and LVH; Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes; HRT, Lipid, and Glucose Metabolism in Diabetic and Nondiabetic Postmenopausal Women
-
The FDA has approved Ezetimibe, the first drug in a new class of cholesterol-lowering medications.
-
Although several other studies have examined the relationship between analgesic use and blood pressure, this report from the Nurses Health Study is the first prospective look at all 3 classes of over-the-counter analgesics.
-
This randomized controlled study compared surgery vs nocturnal wrist splints in 176 patients with idiopathic carpal tunnel syndrome.
-
Phillips et al have demonstrated that increasing muscular aches and pains often associated with decreased exercise tolerance may, in fact, be due to statin therapy even in patients with normal CPK determinations.
-
The emergence of chronic wasting disease, a transmissible spongiform encephalopathy in North American cervids, raises concern about potential transmission to humans, as has occurred elsewhere with bovine spongiform encephalopathy and vCJD.
-
MRC/BHF Heart Protection Study of Antioxidant Vitamin Supplementation
in 20,536 High-Risk Individuals; Prolonged Erections Produced by
Dihydrocodeine & Sildenafil; Effect of Magnesium Supplementation of
Blood Pressure; Homocysteine-Lowering Therapy with Folic Acid,
Vitamins, and Clinical Outcome after Percutaneous Coronary
Intervention; Effect of Cataract Surgery on Motor Vehicle Accidents in
Older Adults; Inflammatory Biomarkers, Hormone Replacement Therapy, and
Incident Coronary Heart Disease
-
Debate over the cardiovascular effects of COX-2 inhibitors has raged
for more than a year since a special communication was published in
JAMA last August suggesting an increase in cardiovascular events with
rofecoxib (Vioxx). Now a large retrospect, the cohort study from the
Tennessee Medicaid program seems to confirm the prothrombotic effects
of rofecoxib, at least in high dose.
